Early Rheumatoid Arthritis: New Treatment Delays Disease Onset by Years

For many, the first twinge of joint pain sparks a deep fear: could this be the beginning of a debilitating, lifelong illness? Facing the challenge of polyarthrite rhumatoïde, an autoimmune disease that remains incurable, a common question arises – can intervention occur before the disease fully establishes itself, buying valuable years of relief?

A Potential Window of Opportunity

This inflammatory condition affects between 0.5 and 1% of the adult population; in 2019, 18 million people worldwide were living with the disease. Without treatment, polyarthrite rhumatoïde causes painful, warm, swollen joints and can lead to irreversible damage, as well as cardiac or pulmonary complications. Now, a team at King’s College London has added a significant piece to the puzzle: early treatment of polyarthrite rhumatoïde in individuals at very high risk could delay the onset of the disease for years – sometimes up to four.

Abatacept and High-Risk Adults

While effective treatments exist for those with established polyarthrite rhumatoïde, there are currently no approved therapies to prevent the disease from developing in at-risk individuals.

The APIPPRA trial involved 213 adults from the United Kingdom and the Netherlands experiencing inflammatory joint pain, but without definitive swelling. Crucially, these participants tested positive for specific auto-antibodies (ACPA and rheumatoid factor) in blood tests. This profile indicates a “at risk” phase, or pre-polyarthrite, where the probability of developing the disease within two years is particularly high.

Participants received either abatacept via weekly injection for 12 months, or a placebo. After one year, only 6% of those treated with abatacept had developed polyarthrite rhumatoïde, compared to 29% in the placebo group. At 24 months, these figures were 25% versus 37%. During treatment, patients receiving abatacept also reported significant improvements in pain, fatigue, sleep, and their ability to work. Professor Andrew Cope, Professor of Rheumatology at King’s College London’s Centre for Rheumatic Diseases, summarized the findings: “Intervenir précocement chez les personnes à haut risque de polyarthrite rhumatoïde peut avoir des effets bénéfiques durables. Nous avons démontré que cette approche est sûre et permet de prévenir la maladie pendant le traitement, tout en soulageant considérablement les symptômes. Surtout, elle peut retarder l’apparition de la polyarthrite rhumatoïde durant plusieurs années, même après l’arrêt du traitement. Cela pourrait réduire la durée pendant laquelle les personnes vivent avec les symptômes et les complications, améliorant ainsi considérablement leur qualité de vie.”

Delaying, Not Eliminating, the Disease

Long-term follow-up, spanning four to eight years, revealed the benefit extends beyond the final injection. Individuals who received abatacept took significantly longer to develop polyarthrite rhumatoïde than those on placebo, with a delay of up to four years after the 12-month treatment period ended. This effect was most pronounced in individuals with the highest risk, identified by high levels of auto-antibodies. However, once treatment ceased, symptom levels gradually converged between the two groups, suggesting ongoing immune modulation may be necessary to maintain symptom control.

Researchers describe this as a “suspensif” effect: the treatment alters the disease course by delaying its appearance, but does not prevent it indefinitely. Gaining several years without inflammatory flares or significant disability remains a major benefit for professional life, family, and long-term health. Safety data was reassuring, with similar rates of serious adverse events between the abatacept and placebo groups, though regular medical monitoring remains essential.

What Does This Mean for Patients in France?

Currently, abatacept (Orencia ®) is already used in France to treat established cases of polyarthrite rhumatoïde, particularly when initial conventional treatments have been insufficient. For individuals only “at high risk” – experiencing joint pain and possessing auto-antibodies but without joint swelling – there is currently no preventative treatment authorized for routine use. Medical societies remain cautious, noting that many at-risk individuals will never develop full-blown polyarthrite rhumatoïde, while biologic therapies are complex, costly, and carry a risk of infection.

For those experiencing recurrent joint pain, especially in the morning, or with a family history of polyarthrite rhumatoïde, the immediate step is to consult a rheumatologist. This specialist can assess risk level, order necessary tests, provide close monitoring, and initiate disease-modifying treatment as soon as the polyarthrite rhumatoïde becomes clinically apparent, to limit joint damage. Participation in a clinical trial testing early treatment with abatacept may be an option for a minority of very high-risk patients, always under strict medical supervision.

Frequently Asked Questions

What is polyarthrite rhumatoïde?

Polyarthrite rhumatoïde is an autoimmune disease that causes inflammation of the joints, leading to pain, swelling, and potentially irreversible damage. It affects between 0.5 and 1% of the adult population.

What did the APIPPRA trial show?

The APIPPRA trial demonstrated that abatacept treatment in individuals at high risk of developing polyarthrite rhumatoïde could delay the onset of the disease by up to four years, even after treatment ended.

Is abatacept currently available as a preventative treatment?

Currently, abatacept is not authorized for routine preventative use in individuals at high risk of polyarthrite rhumatoïde. It is used to treat established cases of the disease in France.

What role might early intervention play in managing this condition for those at risk?